首页> Journal of experimental & clinical cancer research : CR> Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.

导出 OA

翻译打印收藏纠错

第一作者： Dipranjan,Laha

第一单位： Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

作者： Dipranjan,Laha ^[1] ; Robert R C,Grant ^[1] ; Prachi,Mishra ^[1] ; Myriem,Boufraqech ^[2] ; Min,Shen ^[3] ; Ya-Qin,Zhang ^[3] ; Matthew D,Hall ^[3] ; Martha,Quezado ^[4] ; Michelly Sampaio,De Melo ^[4] ; Jaydira,Del Rivero ^[5] ; Martha,Zeiger ^[1] ; Naris,Nilubol ^[6]

作者单位： Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. ^[1] Department of Molecular Biosciences, College of Natural Sciences, Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX, USA. ^[2] National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA. ^[3] Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[4] Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[5] Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. naris.nilubol@nih.gov. ^[6]

关键词 Adrenocortical cancer Cyclin-dependent kinase Maternal embryonic leucine zipper kinase Quantitative high-throughput screening Targeted therapy β-catenin